A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
D7860C00005
Phase 1 other active
Quick answer
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus for Type 2 Diabetes Mellitus is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Modality
- other
- Status
- active